Clinical trials: Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period.
- Trial name
- HBMS01 (NCT05116540)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS.
- Trial name
- NCT03085810
- Testing
- Ocrelizumab
- Where
- 193 sites in United States, Argentina and 27 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects.
- Trial name
- Estriol-MS (NCT00451204)
- Testing
- Estriol, Copaxone
- Where
- 16 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles
Relapsing Remitting Multiple Sclerosis
Safety of New Formulation of Glatiramer Acetate
The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA.
- Trial name
- Song (NCT00947752)
- Testing
- Glatiramer Acetate, Experimental Glatiramer Acetate
- Volunteers
- 147 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of Part A is to determine the safety and tolerability of natalizumab administered over 24 weeks in Japanese participants with relapsing-remitting multiple sclerosis (MS).
- Trial name
- Tysabri Japan (NCT01440101)
- Testing
- Natalizumab (BG00002)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug.
- Trial name
- ACCLAIM (NCT01116427)
- Testing
- abatacept
- Where
- 21 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Multiple Sclerosis
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT02634307
- Testing
- ALKS 8700
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 1,057 people
- Sponsor
- Biogen
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis, Relapsing-Remitting
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT02019550
- Testing
- Rebif Rebidose, Rebiject II
- Where
- 21 sites in United States
- Volunteers
- 97 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis (RRMS)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- RED4MS (NCT06430671)
- Testing
- CLS12311 low, CLS12311 medium, CLS12311 high
- Where
- 8 sites in Czechia, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Cellerys AG
Relapsing-Remitting Multiple Sclerosis
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
- Trial name
- NCT00882999
- Testing
- LY2127399
- Where
- 63 sites in United States, Bulgaria and 11 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates…
- Trial name
- EPOC (NCT01534182)
- Testing
- Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA)
- Where
- 26 sites in Russia
- Volunteers
- 298 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02525874
- Testing
- dimethyl fumarate
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 218 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of…
- Trial name
- EMPhASIS (NCT03846219)
- Testing
- IMU-838 (30 mg/day), IMU-838 (45 mg/day), IMU-838 (10 mg/day)
- Where
- 38 sites in Bulgaria, Poland and 2 more
- Volunteers
- 210 people
- Sponsor
- Immunic AG
Multiple Sclerosis, Relapsing-Remitting
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
- Trial name
- NCT00235989
- Testing
- Interferon beta 1b (Betaseron, BAY86-5046)
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- Bayer